Body mass index and bone mass in postmenopausal women: a dilemma in clinical practice
Abstract
ABSTRACT
Introduction: Low weight and obesity are risk factors for osteoporosis in postmenopausal women; however, the influence of its change on a therapeutic response to biophosphonates for the prevention of fractures has not been defined yet.
Objective:To describe the association between the body mass index (BMI) and bone mass in postmenopausal women, as well as to identify changes in weight and BMI during the treatment with biophosphonates.
Material and methods: Weight, height, and BMI was determined in 296 women who came consecutively to the Climateric and Osteoporosis Clinic (ClimOS) in Havana from 2009 to 2014 (n=103), and to the Department of Metabolic Bone Diseases, Jiménez Díaz Foundation, Madrid (n=193); also, bone mineral density in lumbar spine and hip was measured by DXA. The influence of initial body weight and its temporal variation with the use of biophosphonates (BPS) was evaluated in 80 of them. Statistical analysis: standard statistical average for qualitative variables, frequencies for the qualitative variables, Student´s t-Tests, and X2 test for differences among them. Pearson´s correlation to specify the influence of the initial weight and BMI, and their differences in the response to biophosphonates. Besides, p<0,05 value was used for statistical significance.
Results: Low weight was identified 4/296; more than half of them were overweight or obese. Women who were evaluated in ClimOs, presented a worse bone status on the hip. Neither association of body weight nor BMI was found on the response to treatment with (BPS).
Conclusions: The influence of body weight on a new fracture was controversial; it is suggested to include ponderal variation as part of the treatment for osteoporosis.
Keywords: menopause, osteoporosis, body mass index, biophosphonates, body composition.
Downloads
References
1. National Osteoporosis Foundation. Fast facts. Available at: https://www.iofbonehealth.org/facts-statistics#category-24 (Acceso 17 de abril 2017.)
2. Cummings S., CosmanF,Lewiecki M, Schousboe JT, Bauer DC, Black DM et al. Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. JBMR 2017: 32( 1) 3–10).
3. Weaver CM., Gordon K. F. Janz H. J. Kalkwarf J. M. Lappe R. et al The National Osteoporosis Foundation’s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. OsteoporosInt (2016) 27:1281–1386.
4. Bonnick SL.: Bone densitometry in clinical practice, Chapter 8 and 9. Humana Press. Totoma New Jersey, 2004. Page 179-274.
5. Zarate A., Hernández M., Moran C., Ángeles L.: El enfoque moderno de la osteoporosis. Rev Fac Med UNAM 2001:46;48-51.
6. Guía para el diagnóstico y tratamiento de la osteoporosis. Rev Cubana Endocrinol [Internet]. 2014 Abr [citado 2017 Mar 15] ; 25( 1 ): 1-34. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532014000100001&lng=es.
7. SIBOMM 2009 Consenso iberoamericano de osteoporosis.: Osteoporosis: Prevención,Diagnóstico y Tratamiento.
http://www.spodom.org/download
/Consenso_SIBOMM2009.pdf Acceso 15 marzo 2016
8. Shapses SA., Sukumar D. Bone Metabolism in Obesity and Weight Loss.Annu Rev Nutr. 2012 21;: 287–309.
9. Cao JJ .: Effects of obesity on bone metabolism. Journal of Orthopaedic Surgery and Research 2011, 6:30 http://www.josr-online.com/content/6/1/30.Acceso 18 abril 2017
10. Ortega Álvarez FR., Rosas Santillana J.,Barredo Moyano A.,Párraga Aliaga T.: Guía de Práctica Clínica sobre Osteoporosis y Prevención de Fracturas por Fragilidad. http://www.guiasalud.es/GPC/GPC_476_Osteoporosis_AIAQS_compl.pdf
11. Greenspan, S. L.Wymn A., Hoover FH.,Adami S., Gehlbach S., Anderson FA et al. Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J. Am. Geriatr. Soc.2012: 60, 455–461.
12. Hernlund, E. Svedborm A., Ivrgard J.,Compston C., Cooper J., Stenmark J et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden: A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). . Archives of Osteoporosis 2013:8; 136 -141.
13. Cheng LI., Durden E.,Limone B.,RadbillL.,Juneau P.,Spangler L et al: Persistence and compliance with osteoporosis therapies among women in a commercially insured population in the United States . J Manag Care Spec Pharm, 2015 ;21:824-833.
14. .Rexhepi S., Bahtiri E.,Rexhepi M, Sahatciu-Meka V, Rexhepi B.: Association of body weight and body mass index with bone mineral density in women and men from Kosovo. Mater Sociomed 2017:27(4):259-262.
15. López-Gómez JJ, Pérez Castrillón JL, de Luis Román DA .: Impact of obesity on bone metabolism. Endocrinol Nutr. 2016 ;63(10):551-559. doi: 10.1016/j.endonu.2016.08.005. Epub 2016 Oct 12.)
16. Shapses SA, Pop LC, Wang Y Obesity is a concern for bone health with aging. Nutr Res. 2017;39:1-13. doi: 0.1016/j.nutres.2016.12.010. Epub 2017 Jan 18.
17. Xu W, Ni C, Yu R, Gu G, Wang Z, Zheng G.: Risk factors for distal radius fracture in postmenopausal women. Orthopade. 2017 Mar 3. doi: 10.1007/s00132-017-3403-9. [Epub ahead of print])
18. Yang S, Center JR, Eisman JA, Nguyen TV, Association between fat mass, lean mass, and bone loss: the Dubbo Osteoporosis Epidemiology Study. Osteoporos Int. 2015; 26:1381-6.
19. Determinación del índice de masa corporal (índice de Quetelet).http://www.saludmed.com/LabFisio/PDF/LAB_I23-Indice_Masa_Corporal.pdf
20. Del Pino Montes J Osteoporosis: Concepto e importancia. Cuadro clínico. Rev. Osteoporos Metab Miner 2010; 2 (Supl 4): S15-S20
21. II Consenso cubano de climaterio y menopausia. Editorial CIMEQ 2005, La Habana Cuba
22. Oliveri B.,Mastaglia S.: Patogenia de la osteoporosis .http://www.aulavirtual-exactas.dyndns.org/claroline/backends/download.php?url=L01PRFVMT19NRVRBQk9MSVNNT19GT1NGT0NBTENJQ08vQ2xh Acceso 15 marzo 2017).
23. Bijlsma AY., Meskers CGM., Ling C., Narici M., Kurrle SE., Cameron ID et al: Defining sarcopenia: the impact of different diagnostic criteria on the prevalence of sarcopenia in a large middle aged cohort. AGE 2013; 35:871–881.
24. Hernández Rodríguez J, Licea Puig M., Castelo Elías-Calles L. Algunos aspectos de interés relacionados con la obesidad sarcopénica. Rev Cubana Endocrinol [Internet]. 2015 Dic [citado 2017 Mar 15] ; 26( 3 ):. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532015000300007&lng=es.
25. Gnudi S, Sitta E, Fiumi N. Relationship between body composition and bone mineral density in women with and without osteoporosis: relative contribution of lean and fat mass. J Bone Miner Metab. 2007;25: 326-32.
26. Douchi T, Matsuo T, Uto H, KawahataT.,Oki T, Nagata Y.: Lean body mass and bone mineral density in physically exercising postmenopausal women. Maturitas 2003;45: 185-90.
27. Lan T Ho-Pham, Nguyen D Nguyen, Thai Q Lai and Tuan V Nguyen Contributions of lean mass and fat mass to bone mineral density: a study in postmenopausal women.BMC Musculoskeletal Disorders 2010, 11:59. http://www.biomedcentral.com/1471-2474/11/59
28. Sánchez JC. ,Romero CR., Muñoz LV., Alonso Rivera R.: El órgano adiposo, un arcoíris de regulación metabólica y endocrina. Rev Cubana Endocrinol. 2016;27(1)
http://www.revendocrinologia.sld.cu/index.php/endocrinologia/article/view/22 Acceso 16 marzo 2017
29. Argent J. ,Chowen J.A. Nuevas funciones endocrinas de la leptina. Revista Española de endocrinología pediátrica 2014;5: 43-55.
30. Zhu K, Hunter M, James A, Lim EM, Walsh JP. Associations between body mass index, lean and fat body mass and bone mineral density in middle-aged Australians: The Busselton Healthy Ageing Study. Bone. 2015 74:146-52
31. Gourlay ML., Hammett-Stabler CA., Renner JB., Rubin JE.: Associations between body composition, hormonal and lifestyle factors, bone turnover, and BMD.J Bone Metab 2014;21:61-68.
32. Freitas PM, Garcia Rosa ML, Gomes AM, Wahrlich V, Di Luca DG, da Cruz Filho RA, et al.: Central and peripheral fat body mass have a protective effect on osteopenia or osteoporosis in adults and elderly?Osteoporos Int. 2016 ;27(4):1659-63. doi: 10.1007/s00198-015-3414-5. Epub 2015 Dec 9.
33. Mithal A, Bonjour JP., Boonen S-. Burckhardt P., Degens H.,G. El Hajj Fuleihan et al Impact of nutrition on muscle mass, strength, and performance in older adults. Osteoporos Int 2013; 24: 1555-66.
34. Hernández Rodríguez J., Duchi Jimbo PN.: Índice cintura/talla y su utilidad para detectar riesgo cardiovascular y metabólico. Rev Cubana de Endocrinol 2015;26(1):66-76
35. García de Diego R., Prado Martínez C.: Influencia de la composición corporal, el patrón nutricional y el consumo de suplementos farmacológicos de calcio y vitamina D sobre el riesgo de fractura en mujeres menopáusicas. Trabajo de Fin de Grado. Universidad Autónoma de Madrid. Facultad de Ciencias. 2015
36. Diez-Perez A, Naylor KE, Abrahamsen B, Agnusdei D, Brandi ML, Adherence Working Group of the International Osteoporosis Foundation and the European Calcified Tissue Society: International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int. 2017 ; 28(3):767-774.
37. Schurman León, Bagur Alicia, Claus-HermbergHaraldo, Messina Osvaldo D., Negri Armando L., Sánchez Ariel et al . Guías 2012 para el diagnóstico, la prevención y el tratamiento de la osteoporosis. Medicina (B. Aires) [Internet]. 2013 Feb [citado 2017 Mar 15] ; 73( 1 ): 55-74. Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802013000100014&lng=es.Acceso 15 marzo 2017.
38. Martin KE., YuJ, Campbel E., Abarca J., White TJ: Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and All-Cause Cost. J Manag Care Pharm. 2011; 17(8):596-609.
Download PDF
